CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
EpoCan investigates the long-term risks associated with erythropoietin treatment in cancer patients and those with chronic kidney disease. The project aims to identify potential hazards, develop predictive tools, and evaluate the safety and efficacy of epoetin therapies.
EpoCan aims to develop and implement a comprehensive interdisciplinary strategy to assess the long-term risks of erythropoietin (EPO) and its derivatives (epoetins) on tumour growth progression and thromboembolic events in cancer patients, cardiovascular events, and the development of cancer in chronic kidney disease.
Approximately 400,000 patients across Europe receive epoetins treatment each year.
Recent meta-analysis data have raised concerns over increased mortality in some patient groups. H…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom, Belfast
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, ZURICH
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Essen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Madrid
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
